Orizo Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.70 Cr
as on 17-12-2024
- Paid Up Capital ₹ 1.70 Cr
as on 17-12-2024
- Company Age 3 Year, 5 Days
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2023)
- Profit 99.79%
(FY 2023)
- Ebitda 99.79%
(FY 2023)
- Net Worth -0.11%
(FY 2023)
- Total Assets -0.11%
(FY 2023)
About Orizo Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.70 Cr and a paid-up capital of Rs 1.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
Amol Walke, Zubin Gandhi, Punit Thakrar, and One other member serve as directors at the Company.
- CIN/LLPIN
U24290TG2022PTC158573
- Company No.
158573
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jan 2022
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Orizo Pharma?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amol Walke  | Director | 24-May-2023 | Current |
| Zubin Gandhi | Director | 24-May-2023 | Current |
| Punit Thakrar | Director | 24-May-2023 | Current |
| Yatin Desai | Director | 24-May-2023 | Current |
Financial Performance of Orizo Pharma.
Orizo Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 99.79% increase in profit. The company's net worth dipped by a decrease of 0.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orizo Pharma?
Unlock access to Orizo Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Esteem Industries Private LimitedActive 23 years 16 daysAmol Walke and Zubin Gandhi are mutual person
Difgen Pharmaceuticals Private LimitedActive 2 years 8 monthsAmol Walke, Zubin Gandhi and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orizo Pharma?
Orizo Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orizo Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orizo Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
